Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1979 1
1980 13
1981 2
1982 6
1983 3
1984 1
1985 7
1986 4
1987 13
1988 13
1989 15
1990 12
1991 13
1992 17
1993 16
1994 22
1995 23
1996 14
1997 26
1998 28
1999 31
2000 47
2001 43
2002 46
2003 66
2004 82
2005 121
2006 113
2007 119
2008 145
2009 146
2010 221
2011 202
2012 241
2013 311
2014 374
2015 425
2016 430
2017 528
2018 568
2019 792
2020 924
2021 1148
2022 1369
2023 1339
2024 1581
2025 94

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,535 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Rha SY, et al. Among authors: luo s. Lancet Oncol. 2023 Nov;24(11):1181-1195. doi: 10.1016/S1470-2045(23)00515-6. Epub 2023 Oct 21. Lancet Oncol. 2023. PMID: 37875143 Clinical Trial.
Pembrolizumab in HER2-Positive Gastric Cancer.
Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, Yañez P, Wyrwicz LS, Shen L, Ostapenko Y, Bilici M, Chung HC, Shitara K, Qin S, Van Cutsem E, Tabernero J, Luo S, Mahave M, Tang Y, Lowery M, Monteiro MMF, Xu L, Shih CS, Sharan KP, Bhagia P, Rha SY. Janjigian YY, et al. Among authors: luo s. N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14. N Engl J Med. 2024. PMID: 39282917 Free PMC article. Clinical Trial. No abstract available.
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation.
Liu W, You D, Lin J, Zou H, Zhang L, Luo S, Yuan Y, Wang Z, Qi J, Wang W, Ye X, Yang X, Deng Y, Teng F, Zheng X, Lin Y, Huang Z, Huang Y, Yang Z, Zhou X, Zhang Y, Chen R, Xu L, Li J, Yang W, Zhang H. Liu W, et al. Among authors: luo s. Cell Metab. 2024 Oct 1;36(10):2245-2261.e6. doi: 10.1016/j.cmet.2024.08.005. Epub 2024 Sep 6. Cell Metab. 2024. PMID: 39243758
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity.
Lyu YX, Fu Q, Wilczok D, Ying K, King A, Antebi A, Vojta A, Stolzing A, Moskalev A, Georgievskaya A, Maier AB, Olsen A, Groth A, Simon AK, Brunet A, Jamil A, Kulaga A, Bhatti A, Yaden B, Pedersen BK, Schumacher B, Djordjevic B, Kennedy B, Chen C, Huang CY, Correll CU, Murphy CT, Ewald CY, Chen D, Valenzano DR, Sołdacki D, Erritzoe D, Meyer D, Sinclair DA, Chini EN, Teeling EC, Morgen E, Verdin E, Vernet E, Pinilla E, Fang EF, Bischof E, Mercken EM, Finger F, Kuipers F, Pun FW, Gyülveszi G, Civiletto G, Zmudze G, Blander G, Pincus HA, McClure J, Kirkland JL, Peyer J, Justice JN, Vijg J, Gruhn JR, McLaughlin J, Mannick J, Passos J, Baur JA, Betts-LaCroix J, Sedivy JM, Speakman JR, Shlain J, von Maltzahn J, Andreasson KI, Moody K, Palikaras K, Fortney K, Niedernhofer LJ, Rasmussen LJ, Veenhoff LM, Melton L, Ferrucci L, Quarta M, Koval M, Marinova M, Hamalainen M, Unfried M, Ringel MS, Filipovic M, Topors M, Mitin N, Roy N, Pintar N, Barzilai N, Binetti P, Singh P, Kohlhaas P, Robbins PD, Rubin P, Fedichev PO, Kamya P, Muñoz-Canoves P, de Cabo R, Faragher RGA, Konrad R, Ripa R, Mansukhani R, Büttner S, Wickström SA, Brunemeier S, Jakimov S, Luo S, Rosenzweig-Lipson S, Tsai SY, … See abstract for full author list ➔ Lyu YX, et al. Among authors: luo s. Aging (Albany NY). 2024 Oct 16;16(20):12955-12976. doi: 10.18632/aging.206135. Epub 2024 Oct 16. Aging (Albany NY). 2024. PMID: 39418098 Free PMC article. Review.
Cohort Profile: South China Cohort.
Yang J, Luo S, Liu Y, Hong M, Qiu X, Lin Y, Zhang W, Gao P, Li Z, Hu Z, Xia M; South China Cohort (SCC) Collaborative Group. Yang J, et al. Among authors: luo s. Int J Epidemiol. 2024 Feb 14;53(2):dyae028. doi: 10.1093/ije/dyae028. Int J Epidemiol. 2024. PMID: 38412541 No abstract available.
Nanotechnology's application in Type 1 diabetes.
Pan W, Zheng X, Chen G, Su L, Luo S, Wang W, Ye S, Weng J, Min Y. Pan W, et al. Among authors: luo s. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Nov;12(6):e1645. doi: 10.1002/wnan.1645. Epub 2020 May 22. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020. PMID: 32558337 Review.
Transcriptional activation and phosphorylation of OsCNGC9 confer enhanced chilling tolerance in rice.
Wang J, Ren Y, Liu X, Luo S, Zhang X, Liu X, Lin Q, Zhu S, Wan H, Yang Y, Zhang Y, Lei B, Zhou C, Pan T, Wang Y, Wu M, Jing R, Xu Y, Han M, Wu F, Lei C, Guo X, Cheng Z, Zheng X, Wang Y, Zhao Z, Jiang L, Zhang X, Wang YF, Wang H, Wan J. Wang J, et al. Among authors: luo s. Mol Plant. 2021 Feb 1;14(2):315-329. doi: 10.1016/j.molp.2020.11.022. Epub 2020 Dec 2. Mol Plant. 2021. PMID: 33278597 Free article.
10,535 results
You have reached the last available page of results. Please see the User Guide for more information.